scholarly journals Association of C1q/TNF-related protein-1 (CTRP1) serum levels with coronary artery disease

2019 ◽  
Vol 47 (6) ◽  
pp. 2571-2579 ◽  
Author(s):  
Linhui Shen ◽  
Shuhong Wang ◽  
Yuan Ling ◽  
Wei Liang

Objective Complement C1q tumor necrosis factor-related proteins (CTRPs), belonging to the CTRP superfamily, are extensively involved in regulating metabolism and the immune-inflammatory response. The inflammatory process is linked to the pathogenesis of coronary artery disease (CAD). Here, we investigated the association of serum levels of CTRP1 with CAD. Methods Study participants were divided into two groups according to the results of coronary angiography: a control group (n = 63) and a CAD group (n = 76). The concentrations of serum CTRP1 and inflammatory cytokines were determined by enzyme-linked immunosorbent assay. Further analysis of CTRP1 levels in individuals with different severities of CAD was conducted. The CAD severity was assessed by Gensini score. Results Serum levels of CTRP1 were significantly higher in CAD patients than in controls (17.24 ± 1.07 versus 9.31 ± 0.56 ng/mL), and CTRP1 levels increased with increasing severity of CAD. CTRP1 levels were positively correlated with concentrations of tumor necrosis factor-α and interleukin-6. Multiple logistic regression analysis showed that CTRP1 was significantly associated with CAD. Conclusions Our data showed close associations of serum CTRP1 levels with the prevalence and severity of CAD, indicating that CTRP1 can be regarded as a novel and valuable biomarker for CAD.

2021 ◽  
Vol 12 (4) ◽  
pp. 137-144
Author(s):  
Svetlana V. Topolyanskaya ◽  
Tatyana A. Eliseeva ◽  
Irina E. Godovkina ◽  
Irina S. Vasilieva ◽  
Olga N. Vakulenko ◽  
...  

2019 ◽  
Vol 28 (6) ◽  
pp. 573-580
Author(s):  
Ahmet Seyfeddin Gurbuz ◽  
Semi Ozturk ◽  
Suleyman Cagan Efe ◽  
Mehmet Fatih Yilmaz ◽  
Raziye Ecem Yanik ◽  
...  

Objective: Heparanase (HPA), mammalian endo-β-D-glu­cu­ronidase, separates heparan sulfate chains of proteoglycans and changes the structure of the extracellular matrix. We investigated whether serum levels of HPA differ in patients with stable coronary artery disease (SCAD) and subjects with normal coronary arteries. Methods: This study enrolled 92 patients with SCAD and 34 controls with normal coronary arteries. Levels of HPA were measured by a commercially available human HPA enzyme-linked immunosorbent assay kit. Results: Serum HPA levels were significantly lower in the SCAD group (137.5 [104.1–178.9] vs. 198.8 [178.2–244.9] pg/mL; p < 0.001). Serum HPA levels were significantly higher in subjects with diabetes mellitus (DM) compared to those without DM (p = 0.008). Levels of HPA were lower in the SCAD group, both in the diabetic and nondiabetic subgroups, as compared to controls (p < 0.001 for both subgroups). Levels of HPA positively correlated with fasting blood glucose (FBG) (r: 0.42; p < 0.001). In multiple logistic regression analysis, serum HPA level (odds ratio [OR]: 0.975; 95% confidence interval [CI]: 0.966, 0.985; p < 0.001) and FBG (OR: 1.028; 95% CI: 1.010, 1.047; p = 0.002) were independently associated with SCAD. The receiver operating characteristic curve showed that HPA levels less than 160.6 pg/mL predicted SCAD with 65% sensitivity and 97% specificity (AUC: 0.80; 95% CI: 0.728, 0.878; p < 0.001). Conclusion: Diabetes and FBG levels were closely associated with serum levels of HPA. Low serum levels of HPA may predict SCAD in both diabetic and nondiabetic populations.


Sign in / Sign up

Export Citation Format

Share Document